Day: March 1, 2022

CAMBRIDGE, Mass. and GOSSELIES, Belgium, March 01, 2022 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. ET. A live webcast of the virtual presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos Therapeutics, Inc.iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and...

WATERTOWN, Mass., March 01, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 10:30 a.m. ET. A live webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event. About EyePoint Pharmaceuticals EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help...

WESTMINSTER, Colo., March 01, 2022 (GLOBE NEWSWIRE) — ZimVie Inc. (Nasdaq: ZIMV) today announced its debut as an independent publicly traded company and the completion of its separation from Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH). This separation completes the path ZimVie began in 2021 when its former parent company announced its intention to separate its Dental and Spine businesses into one of the world’s newest and leading life sciences companies. ZimVie common stock began “regular way” trading under the symbol “ZIMV” on the Nasdaq Stock Market. “As an independent company, we are uniquely poised to expand the reach of our Dental and Spine product platforms through innovation and enhanced commercial and operational focus,” said Vafa Jamali, President and Chief Executive Officer of ZimVie. “Our solutions hold strong positions...

Industry Leading Peripheral Nerve Stimulator Upgraded to Improve Patient User Experience with Control of their Unique Chronic Pain Condition, Longer Battery Life DURHAM, N.C., March 01, 2022 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced that the US Food and Drug Administration (FDA) has awarded 510(k) clearance to the next generation StimRouter® Neuromodulation System for the treatment of chronic pain of peripheral nerve origin, excluding craniofacial pain. StimRouter is a minimally invasive neuromodulation medical device consisting of a thin, implanted lead with conductive electrode, external electric field conductor (E-EFC), and StimRouter Plus Mobile Application. Electrical signals are transmitted transcutaneously from the E-EFC and...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S. CALGARY, Alberta, March 01, 2022 (GLOBE NEWSWIRE) — Acceleware Ltd. (“Acceleware”) (TSXV: AXE), a Canadian clean-tech innovator of radio frequency (RF) heating technologies today announced that it is launching a non-brokered private placement of 10% unsecured convertible debentures due 2026 (the “Debentures”), for approximate gross proceeds of $1,500,000 (the “Private Placement”). Details of the Private Placement Each Debenture matures four years after the issue date and is convertible into units of Acceleware at a conversion price of $0.80. If Acceleware subsequently sells common shares (or securities that are convertible into or exchangeable for common shares) at a lower purchase (or conversion) price, the conversion price of the Debentures will be adjusted...

VANCOUVER, British Columbia, March 01, 2022 (GLOBE NEWSWIRE) — XR Immersive Tech Inc. (“Immersive Tech”, or the “Company”) (CSE: VRAR) (FSE: 79W) (OTCQB: FNTTF) today announces that Tim Bieber, CEO will be presenting at the Q1 Virtual Investor Summit. During the presentation, Tim Bieber, XR Immersive Tech CEO will highlight the Company’s focus on building Metaverse tools, the release of it’s Hyper-Immersive™ UNCONTAINED VR attraction, it’s recent acquisition of Synthesis VR, and the broader going-forward corporate vision. The presentation will be webcast and an archived recording will be made available in Investors’ section of the XR Immersive Tech Bio website.Event: Q1 Investor SummitDate: March 8-9th, 2022Presentation: March 8th @ 2:00PM ETLocation: Public webcasting linkOn behalf of the Board of Directors Tim...

Record Fourth Quarter Net Sales, Net Income, Adjusted EBITDA and Adjusted EBITDA Margin Net sales of $4.6 billion increased 23.7% on a combined pro forma basisCore Organic Sales Growth of 11.7% on a combined pro forma basisGross profit of $1.5 billion increased 52.5% on a combined pro forma basisAdjusted EBITDA increased 110.0% to $793.4 million on a combined pro forma basis DALLAS, March 01, 2022 (GLOBE NEWSWIRE) — Builders FirstSource, Inc. (NYSE: BLDR) today reported its results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 BFS Highlights (includes BMC in Q4 2021 and not in Q4 2020) All Year-Over-Year Comparisons Unless Otherwise Noted:Net sales of $4.6 billion for the quarter increased 83.1% driven by the merger with BMC, double-digit organic growth, and commodity inflation Gross profit...

— Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval — — First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 – — Enrollment completed in Phase 2 trial evaluating setmelanotide in patients with hypothalamic obesity — — IMCIVREE fourth quarter sales of $1.8M and 2021 sales of $3.2M – — Management to host conference call today at 8:00 a.m. ET — BOSTON, March 01, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2021. “2021 was a...